Therapy Areas: Allergy
Argo Biopharmaceutical to present BW-20805 Phase II interim data at AAAAI 2026 Annual Meeting
26 February 2026 - Argo Biopharmaceutical Co Ltd, a China-based, clinical-stage small interfering RNA (siRNA) therapeutics company, announced on Wednesday that it has been selected as a late breaking ...
Reacta Healthcare names new chair of board
20 February 2026 - Reacta Healthcare Ltd, a UK-based developer of food allergy diagnostic products, announced on Thursday the appointment of Richard Nagle as chair of its board of directors.Nagle has ...
GSK agrees to acquire RAPT Therapeutics to strengthen food allergy pipeline
20 January 2026 - UK biopharmaceutical company GSK plc (LSE/NYSE: GSK) on Tuesday announced a definitive agreement to acquire RAPT Therapeutics (NASDAQ:RAPT), a California-based clinical-stage biophar...
Elanco Animal Health's Befrena (tirnovetmab) receives USDA approval for canine dermatitis
2 January 2026 - Animal health specialist Elanco Animal Health Incorporated (NYSE:ELAN) announced on Wednesday that it has received approval from the US Department of Agriculture (USDA) for Befrena (t...
Blacksmith Medicines granted European patent for LpxC-targeting antibacterial compounds
25 November 2025 - Blacksmith Medicines Inc, a biopharma company focused on discovering and developing therapeutics targeting metalloenzymes, announced on Monday that the European Patent Office has is...
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
20 October 2025 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Monday that it has received US Food and Drug Administration (FDA) approval for Tezspire (te...